Description
Lulizumab(TD-HY422016) is a research-grade recombinant antibody targetingCD28. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.